Podcast | Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)

Course Title for Certificate

Name*

First NameLast Name

Email*

example@example.com

What best describes your title?*

If PharmD, DOB

Date

If PharmD, NABP ID#:

How many years have you been in practice?

1. Which of the following statements is false?*

a. The classic dose-response where clinical effectiveness increases with dose is not always seen in lupus with immune modulating treatmentsb. Myeloid cells are important in regulating B-cell survival and differentiation through secretion of BLys (BAFF)c. CAR T-cell therapy avoids the problems seen with rituximab that may be caused by increased BLySd. Longterm drug-free remission for up to a year or more has occurred in some SLE patients receiving CAR T-cell therapy

2. An advantage of CAR T-cell treatment in systemic lupus erythematosus (SLE) is:*

a. Once the complex administrative process is completed, many patients may reduce or stop other immune modulating treatments and remain well for many months or moreb. It puts all patients with lupus into remission regardless of their individual pathologyc. There is no risk for neurologic side effects in SLEd. It is relatively inexpensive compared to the use of these agents in cancer

3. A major disadvantage of autologous CAR T-cell treatment in SLE is:*

a. A high incidence of ICANS (Immune Cell Associated Neurotoxicity Syndrome)b. Delays in treatment due to the process needed to manufacture the cellsc. A high incidence of high-grade CRS (cytokine release syndrome)d. It is effective in only a small minority of patients

How many patients do you currently see each month regarding severe refractory systemic lupus erythematosus (SLE)?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology and mode of action of CAR T-cell therapy
Review the current clinical options, unmet needs, and emerging therapies for patients with severe, refractory systemic lupus erythematosus
Analyze the clinical trial data and clinical applications of CAR T-cell therapy to treat patients with severe, refractory SLE
Develop strategies to incorporate patient shared decision making when discussing CAR T-cell therapy for SLE

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall
Content
Usefulness

Do you feel this activity was fair, balanced, and free of commercial bias?

YesNo

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What factors beyond clinical care that effect the health of your patients does your team experience?

Attestation:

AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. AcademicCME designates this enduring material for a maximum of 1.25 CNE Contact Hours. AcademicCME designates this continuing education activity for 1.25 CPE Contact Hours (.125 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-25-032-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Date

Credits